BRISBANE, Calif., Oct. 27 /PRNewswire-FirstCall/ -- CoTherix, Inc. announced today that Donald J. Santel, Chief Executive Officer, will provide a company overview at two upcoming investor conferences. A live transmission of the presentations will be available through the CoTherix website at http://www.cotherix.com/. The following is the schedule of presentations:
* Monday, November 6, 2006, 10:35a.m. ET, Rodman & Renshaw 8th
Annual Healthcare Conference
* Wednesday, November 8, 2006, 9:45a.m. ET, CIBC World Markets
17th Annual Healthcare Conference
About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiovascular disease. CoTherix currently markets Ventavis(r) (iloprost) Inhalation Solution in the United States for the treatment of PAH (WHO Group I). The Company is also developing fasudil, a rho-kinase inhibitor, for the treatment of PAH and stable angina. CoTherix and the CoTherix logo are trademarks of CoTherix, Inc. Ventavis is a registered trademark of Schering AG. More information can be found at http://www.cotherix.com/ or http://www.4ventavis.com/.
